Keros Therapeutics, Inc. (KROS)
| Market Cap | 230.33M -59.1% |
| Revenue (ttm) | 244.06M +6,775.0% |
| Net Income | 87.01M |
| EPS | 2.30 |
| Shares Out | 19.79M |
| PE Ratio | 5.06 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 157,107 |
| Open | 11.73 |
| Previous Close | 11.78 |
| Day's Range | 11.35 - 11.74 |
| 52-Week Range | 10.42 - 22.55 |
| Beta | 0.95 |
| Analysts | Buy |
| Price Target | 21.86 (+87.8%) |
| Earnings Date | May 19, 2026 |
About KROS
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for KROS stock is "Buy." The 12-month stock price target is $21.86, which is an increase of 87.80% from the latest price.
News
Keros Therapeutics Transcript: Leerink Global Healthcare Conference 2026
Significant progress included the transition of elritercept to Takeda, advancement of rinvatercept into DMD and ALS, and discontinuation of cibotercept. Rinvatercept showed promising Phase 1 results, and the ALS program was selected for a major consortium trial. Early pipeline expansion and a strong financial runway extend into 2028.
Keros Therapeutics announces collaboration with Sean M. Healey & AMG Center
Keros Therapeutics (KROS) announced that it has entered into an agreement with the Massachusetts General Hospital, MGH, for the design of a Phase 2 clinical trial evaluating rinvatercept in patients
Keros Therapeutics presents additional data from Phase 1 of rinvatercept
Keros Therapeutics (KROS) announced that it presented additional data from its Phase 1 clinical trial of rinvatercept in healthy volunteers at the 2026 Muscular Dystrophy Association Clinical & Scient...
Keros Therapeutics Presents Additional Clinical Data from Its Rinvatercept Program at the 2026 MDA Clinical & Scientific Conference
LEXINGTON, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercial...
Keros Therapeutics Announces Collaboration with Sean M. Healey & AMG Center for ALS
LEXINGTON, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercial...
Keros Therapeutics price target lowered to $20 from $23 at Wells Fargo
Wells Fargo lowered the firm’s price target on Keros Therapeutics (KROS) to $20 from $23 and keeps an Overweight rating on the shares. The firm notes no change to its
Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results
LEXINGTON, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercial...
Keros Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference
Rinvatercept (KER-065) is advancing to phase II trials in DMD and ALS, showing strong preclinical and phase I data for muscle, bone, and fat improvements. The DMD trial will focus on late ambulatory and early non-ambulatory cohorts, with initial combination therapy alongside glucocorticoids. Significant Takeda partnership supports the pipeline.
Keros Therapeutics Appoints Charles Newton to its Board of Directors
LEXINGTON, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commerciali...
Keros Therapeutics Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference
The company is advancing rinvatercept for DMD and ALS, with a DMD trial starting this quarter and ALS regulatory engagement planned for the second half of the year. Elritercept, partnered with Takeda, is in phase III for MDS and MF, with commercialization targeted for late this decade. Cash reserves of $383M provide runway into 2028.
Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences
LEXINGTON, Mass., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commerciali...
Keros Therapeutics price target raised to $19 from $18 at BofA
BofA analyst Jason Zemansky raised the firm’s price target on Keros Therapeutics (KROS) to $19 from $18 and keeps a Neutral rating on the shares after adjusting projections following the
Keros Therapeutics Announces Final Results of Tender Offer
LEXINGTON, Mass., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), today announced the final results of its cash tender offer (the “Tender Offer”) ...
Keros Therapeutics Announces Preliminary Results of Tender Offer
LEXINGTON, Mass., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), today announced the preliminary results of its cash tender offer (the “Tender Of...
Keros Therapeutics price target raised to $27 from $23 at Oppenheimer
Oppenheimer analyst Andreas Argyrides raised the firm’s price target on Keros Therapeutics (KROS) to $27 from $23 and keeps an Outperform rating on the shares following quarterly results and business
Keros Therapeutics price target raised to $27 from $23 at Oppenheimer
Oppenheimer analyst Andreas Argyrides raised the firm’s price target on Keros Therapeutics (KROS) to $27 from $23 and keeps an Outperform rating on the shares following quarterly results. The firm
Keros Therapeutics reports Q3 EPS (18c), consensus (92c)
Reports Q3 revenue $14.26M, consensus $4.22M. The net loss decrease of $45.7M was largely due to revenue recognized related to Keros’ license agreement with Takeda, partially offset by research and
Keros Therapeutics Reports Third Quarter 2025 Financial Results
LEXINGTON, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commerciali...
Keros Therapeutics to repurchase $194.4M of shares
Keros Therapeutics (KROS) announced that, as part of its previously announced $375M capital return program, it has commenced a cash tender offer to repurchase up to $194.4M of shares of
Keros Therapeutics Commences Issuer Tender Offer to Repurchase up to $194.4 Million Shares
LEXINGTON, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commerciali...
Keros Therapeutics announces share repurchase program
Keros Therapeutics (KROS) announced that, as part of its previously announced $375M capital return program, it has entered into share purchase agreements to repurchase all of the shares of the
Keros Therapeutics Announces Plan for Return of $375 Million in Excess Capital
Agrees to Repurchase of All Shares Held By ADAR1 Capital Management and Pontifax Venture Capital Plans to Commence Tender Offer to Repurchase up to $194 Million of Additional Shares LEXINGTON, Mass., ...
Keros Therapeutics presents additional clinical data from KER-065 program
Keros Therapeutics (KROS) presented additional clinical data from its Phase 1 clinical trial of KER-065 in healthy male volunteers at the American Society of Bone and Mineral Research 2025 Annual
Keros Therapeutics Presents Additional Clinical Data from its KER-065 Program at the American Society of Bone and Mineral Research 2025 Annual Meeting
LEXINGTON, Mass., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel thera...
Keros Therapeutics Transcript: Wells Fargo 20th Annual Healthcare Conference 2025
Significant strategic changes include asset partnership, pipeline focus on KER-065, and a $375M capital return. KER-065 shows promise in DMD with improved safety and efficacy, while Takeda advances partnered programs. Regulatory and clinical milestones are upcoming.